Difei Yang
Stock Analyst at Mizuho
(2.25)
# 2,748
Out of 5,139 analysts
29
Total ratings
33.33%
Success rate
13.75%
Average return
Main Sectors:
Stocks Rated by Difei Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Downgrades: Neutral | $6 → $2 | $1.18 | +69.49% | 4 | Mar 31, 2022 | |
| NVCR NovoCure | Maintains: Neutral | $229 → $200 | $11.39 | +1,655.93% | 6 | Jul 30, 2021 | |
| CASI CASI Pharmaceuticals | Initiates: Buy | $38 | $0.80 | +4,650.00% | 1 | Apr 26, 2021 | |
| QURE uniQure | Upgrades: Buy | $52 | $24.40 | +113.11% | 4 | Apr 1, 2021 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $158 → $160 | $18.59 | +760.68% | 2 | Feb 26, 2021 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $18 → $14 | $6.73 | +108.02% | 4 | Apr 23, 2020 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $315 → $525 | $73.86 | +610.80% | 4 | Feb 3, 2020 | |
| BOLD Boundless Bio | Upgrades: Buy | n/a | $1.18 | - | 2 | Aug 8, 2018 | |
| RGNX REGENXBIO | Initiates: Neutral | $28 | $8.41 | +232.94% | 1 | Feb 13, 2018 | |
| HRTX Heron Therapeutics | Initiates: Buy | $28 | $1.19 | +2,252.94% | 1 | Sep 27, 2017 |
Akebia Therapeutics
Mar 31, 2022
Downgrades: Neutral
Price Target: $6 → $2
Current: $1.18
Upside: +69.49%
NovoCure
Jul 30, 2021
Maintains: Neutral
Price Target: $229 → $200
Current: $11.39
Upside: +1,655.93%
CASI Pharmaceuticals
Apr 26, 2021
Initiates: Buy
Price Target: $38
Current: $0.80
Upside: +4,650.00%
uniQure
Apr 1, 2021
Upgrades: Buy
Price Target: $52
Current: $24.40
Upside: +113.11%
Sarepta Therapeutics
Feb 26, 2021
Maintains: Buy
Price Target: $158 → $160
Current: $18.59
Upside: +760.68%
Xeris Biopharma Holdings
Apr 23, 2020
Maintains: Buy
Price Target: $18 → $14
Current: $6.73
Upside: +108.02%
Nektar Therapeutics
Feb 3, 2020
Upgrades: Buy
Price Target: $315 → $525
Current: $73.86
Upside: +610.80%
Boundless Bio
Aug 8, 2018
Upgrades: Buy
Price Target: n/a
Current: $1.18
Upside: -
REGENXBIO
Feb 13, 2018
Initiates: Neutral
Price Target: $28
Current: $8.41
Upside: +232.94%
Heron Therapeutics
Sep 27, 2017
Initiates: Buy
Price Target: $28
Current: $1.19
Upside: +2,252.94%